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Background. Based on epidemiological data, clinical trials, and meta-analytic reviews, omega-3 polyunsaturated fatty acids (n-3
PUFAs) seem to be a biological link between depression and cardiovascular diseases (CVDs). Presentation. Involvement of n-3
PUFAs in depression and CVDs may be associated with a chronic, low-grade, inﬂammation. We hypothesize that n-3 PUFAs
link depression and CVDs via “PUFA-prostaglandin E2 (PGE2) cascade.” Testing. To further support our hypothesis, case-control
studies are needed to test the role of COX2 and PLA2 functions in depression and in CVDs. In addition, the eﬀects of n-3 PUFAs
on cardiovascular markers in depression and on depressive symptoms in CVDs should be investigated in clinical trials. Finally, the
eﬀects of manipulating COX2 and PLA2 functions on depression-like behaviors and cardiovascular functions could be explored
in animal studies. Implications. n-3 PUFAs might be a promising treatment for both cardiovascular diseases and depression via its
anti-inﬂammatory, cardioprotective, and neuroprotective eﬀects.
Copyright © 2009 Jane Pei-Chen Chang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
1.1. The Missing Link from “Sadness” to “Heart-Breaking”.
When people are upset or being hurt emotionally, we often
describethemtohavea“brokenheart.”InMandarin,wealso
refer the concept of “sadness”t o“sung-shin ( ),”w h i c h
literally means “heart-breaking.” Although this metaphor
by referring a dysfunctioning brain to a breaking heart is
misleading biologically, accumulating evidence from empir-
ical studies reveal that there seems to be a “mind-body
interface” linking between cardiovascular diseases (CVDs)
and depression.
1.2. The “Linking” between Depression to CVD. Depression
and CVD are two highly comorbid diseases with 15 years of
scientiﬁcevidencesupporting thisphenomenon[1].Depres-
sion has an estimated 10% life prevalence rate in the general
population, while an estimated of 17–27% prevalence rate
of depression is noted in population with CVD [2]. In
addition, depression observed following CVD is common
and associated with increased risk of mortality. Depression is
apotentialprognosticfactortoincreasefuturecardiovascular
event risk by 2–7.5 folds in patients with CVD [3]. One
would expect that depression is the psychological response
to a cardiovascular event; however, depression without any
cardiovascular comorbidity has been found to increase the
odds ratio (OR) for future CVD event (OR = 4.5) in
the 13-year prospective study in Maryland Epidemiological
Catchment Area [4]. Glassman et al. showed that heart rate
variability (HRV) is an indicator reﬂecting ﬂuctuations in
autonomic activity and moderately strong and independent
predictor of death, also, recovery after acute coronary
syndromewasnotobservedinpatientswithmajordepressive
disorder (MDD) [1]. Medically healthy individuals who
suﬀer from depression are also at signiﬁcantly increased
risk of developing heart attacks and strokes later in life [5].
These ﬁndings imply that there might be a common pathway
between depression and CVD.2 Cardiovascular Psychiatry and Neurology
The exact mechanisms interplaying between depression
and CVD are still under investigation, however, clinical
and interventional studies have shown that the bidirectional
relation of the two are connected via adversely aﬀected
autonomic and hormonal homeostasis, which result in
inﬂammation, metabolic abnormalities, hypercoagulability,
and endothelial dysfunction [6]. Low-grade inﬂammation
is one possible common mechanism responsible for the
relationship between CVD and depression. Inﬂammatory
process mediators such as arachidonic acid (AA) and its
metabolites, prostaglandins (PGs) and leukotrienes (LTs),
contribute to diverse circulatory and homeostatic func-
tions [7]. PGs and LTs are highly biologically active, have
proinﬂammatory action, vasoconstriction action, and are
known to be involved in various pathological processes,
such as atherosclerosis and CVD [8]. In patients with major
depression, the inﬂammatory biomarkers including PGE2,
IL-1, IL-6, and IL-12 have been found to be signiﬁcantly
increased as compared with healthy controls [9]. The role
of inﬂammation in depression has also been demonstrated
in animal models when endotoxin (lipopolysaccharide; LPS)
or interleukin-1 (IL-1) is administered to induce sickness
behavior that resembles depression [9]. In addition, depres-
sion is more frequently seen in those with medical disorders
associated with immune dysfunction, for example, diabetes
mellitus [10] and hepatitis C (HCV) patients treated with
interferon alpha [9].
HPA axis hyperactivity has been reported as another
possible mechanism to be associated with major depression
and CVD [11]. Patients with major depression has been
found to have elevated corticotrophin releasing factor (CRF)
concentrations in cerebrospinal ﬂuid (CSF) [12], blunting
of adrenocorticotropic hormone (ACTH) response to CRF
administration, nonsuppression of cortisol secretion follow-
ing dexamethasone administration, and hypercortisolemia
[13]. HPA axis hyperactivity in depression is also shown
by dysregulation of multidrug resistance p-glycoprotein
(MRD PGP), a membrane steroid transporter in the brain
located on blood-brain-barrier [14]. Overactive MRD PGP
in depressed patients reduces the access of glucocorticoids
to brain and induces glucocorticoid resistance [15]. Admin-
istered corticosteroids have long been known to induce
hypercholesterolemia, hypertriglyceridemia, and hyperten-
sion, which simulate the HPA hyperactivity condition in
CVD patients [11]. The dysregulations of blood lipids and
blood pressure predispose and exacerbate CVD. Studies have
shown that elevated morning plasma cortisol concentrations
have been signiﬁcantly correlated with moderate-to-severe
coronary atherosclerosis in young and middle-aged men
[16].
2. Presentationof the Hypothesis
2.1. n-3 PUFAs in Depression and CVD. There are two
main types of bioactive polyunsaturated fatty acids (PUFAs),
the omega-6 (n-6) series (cis-linoleic acid [LA,18 : 2], γ-
linolenic acid [GLA, 18 : 3, n-6], dihomo-GLA [20 : 3, n-6],
arachidonic acid [AA, 20 : 4, n-6]), and the omega-3 (n-3)
series (α-linolenic acid [ALA, 18 : 3], eicosapentaenoic acid
[EPA, 20 : 5, n-3], docosahexaenoic acid [DHA]). However,
n-3 and n-6 PUFAs are important constituents of all cell
membranes and essential for survival of humans and other
mammals. Because the n-3 PUFAs cannot be synthesized in
the body and can only be obtained from our diet, they are
also called essential fatty acids [9].
Based on the evidence from epidemiological data, case-
controlled studies, and clinical trials, n-3 PUFAs have been
found to be important in the development of depression
and CVD. In epidemiological studies, it has been observed
that societies with high consumption of n-3 PUFAs appear
to have lower prevalence of CVD, as well as the prevalence
of depression [17]. In case-controlled studies, lower levels
of n-3 PUFAs have been found in both depression [18]
and CVD patient groups [19]. Besides, the level of n-3
PUFAs is signiﬁcantly negatively correlated with the severity
of depressive symptoms [20]a n dt h e ym a ya c ta sb o t h
prognostic and diagnostic utility in CVD risk assessments
[21]. n-3 PUFAs have antidepressant and antiarrhythmic
eﬀects, as revealed in basic and clinical studies of depressed
patients [22] and CVD patients [23]. Meta-analysis of
omega-3 on CVD with 228864 individuals suggests that
increase in ﬁsh intake, which is abundant with n-3 PUFAs,
was associated with 20% signiﬁcant (P<. 005) reduction
in the risk of fatal CVD and a signiﬁcant (P<. 005) 10%
reduction in total CVD [24]. Many clinical studies showed
that diet of n-3 PUFAs (especially EPA and/or DHA) could
decrease the risk of CVD [25].
If n-3 PUFAs play an important role in depression and
CVD, the enzymes for n-3 PUFA metabolisms might also
have eﬀects on these two diseases. Phospholipase A2 (PLA2)
and cyclooxygenase 2 (COX2) are the two key enzymes of the
PUFA metabolism and PGE2 synthesis [26]. PLA2 is a large
family of enzymes, with Ca2+-independent phospholipase
A2 (iPLA2) preferentially on DHA metabolism and cytolic
PLA2 (cPLA2) preferentially on AA and EPA metabolism
[27, 28]. CPLA2 cleaves PUFAs into free PUFAs and
lysophospholipids, which can modulate signal transduction,
transcriptionalregulation,neuronalactivity,apoptosis,anda
number of other processes within the central nervous system
[29], and the excess activity of the cPLA2 could lower PUFA
response [30]. BanI polymorphism is one of the two gene
polymorphisms of cPLA2 in chromosome 1q25, near the
promoter region and ﬁrst intron [31]. Genetic studies have
revealed that the G allele of BanI polymorphism of cPLA2
increases the risk of developing depression in a Korean
population[32]andtheriskfordepressionamonginterferon
alpha-treated HCV patient groups [33]. COX2 converts AA
to PGE2, and PGE2 relates to development of depression
and CVD via its actions in immunomodulation [34].
A functional G→C polymorphism located 765 basepairs
upstream from the transcription start site (−765G→C) has
been identiﬁed in the human COX2 gene with C allele
leading to decreased promoter activity in vitro [35]. Studies
haveshownthatCallelemightprotectagainstclinicalevents,
for example, myocardial infarction (MI), stroke [36], and
cerebrovascularischemia[37].Callelemayalsobeassociated
wi t hl o w e rl ev e l so fi n ﬂ a m m a t o rym a r k e r ss u c ha sC - r e a c t i v e
protein and interleukin-6 in cardio-/cerebrovascular andCardiovascular Psychiatry and Neurology 3
hypercholesterolemic patients [38]. The C allele of COX2
gene polymorphism has been found to increase risk for CVD
in the Finnish men population [39]. To our knowledge, the
role of COX2 polymorphisms in depression and the role of
PLA2 polymorphisms in CVD have not been conﬁrmed yet.
2.2. Role of n-3 PUFAs in Depression and CVD
2.2.1. Inﬂammation. The PUFAs themselves appear to be
active in the biological function, while some of their
functions require their conversion to eicosanoids and other
products. Figure 1 demonstrates how n-3 and n-6 PUFAs
aﬀect the pathogenesis of depression and CVD and how
n-3 and n-6 PUFAs levels are inﬂuenced by genetic and
environmental factors. The iPLA2 enzyme associates with
n-3 DHA metabolism and cPLA2 enzyme participates in
metabolism of n-6 AA and n-3 EPA [40]. N-6 AA converts
to proinﬂammatory cytokines (PGE2 and LTB4) via COX2
and 5-lipooxygenase (5-LO), in turn, may contribute to the
development of somatic symptoms in depression and the
physical manifestation of CVD [40]. On the other hand, n-
3 DHA might be connected to the etiology of mood and
cognitive dysfunction in depression via its role in neuronal
membrane stability, neuroplasticity, and neurotransmission
[40]. Proinﬂammatory cytokines, such as IL-1, IL-2, and
Interferon gamma (IFN-γ), have been extensively reported
in their eﬀects on activities of PLA2 or COX2 and levels
of n-6 PUFA [41]. Consequently, the activation of PLA2 or
COX2 can induce the release of AA from the membrane
phospholipid [41], and n-3 PUFAs can reduce the activation
of cPLA2 and the release of n-6 AA and PGE 2 induced
by IL-1 [42]. In brief, the n-6 AA can form eicosanoid
series (e.g., PGE2 and LTB4), which has proinﬂammatory,
proaggregatory, and vasoconstrictive eﬀect. n-3 PUFAs can
antagonize n-6 PUFAs and produce oppositional biological
eﬀects.
2.2.2. HPA Axis Hyperactivity. Deﬁciency in the n-3 PUFAs
is associated with increased CSF corticotrophin releasing
hormone (CRH), and contributes to HPA axis hyperactivity
[43]. Animal studies show that the restoration of dietary
DHA normalizes the exaggerated distress behavior of n-3
PUFAs deﬁcient rats during administration of CRH [44].
Double-blind placebo-controlled intervention trials with
human subjects have also demonstrated beneﬁt of stress
protection with n-3 PUFAs dietary supplements. n-3 PUFAs
were shown to attenuate stress-induced increase in aggres-
sion and hostility among Japanese students in one study [45]
and signiﬁcantly reduced perceived stress among stressed
university staﬀ in the other study [46]. Neminen et al. in
2006foundthatlowerlongchainomega-3essentialfattyacid
status was associated with higher neuroactive steroids, such
as 3α,5α-tetrahydrodeoxycorticosterone (THDOC) which
appear to counter-regulate HPA hyperactivity and concen-
trations in human subjects [47] .H P Aa x i sh y p e r a c t i v i t yi s
enhanced through MDR PGP overactivity, which reduces
the access of glucocorticoids to the brain and is found to
contribute to neuronal changes that might lead to depression
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Figure 1: Genetic and environmental factors related to n-3 fatty
acids hypothesis of depression and CVD . The levels of n-3 PUFAs
(n-3 EPA and n-3 DHA) are inﬂuenced by genetic (e.g., PLA2
and COX2 genes on chromosome 1) and environmental (diet,
inﬂammation, or cytokines) factors. n-3 DHA plays a major role in
neuronal membrane stability and functions of signal transduction
and neurotransmission; meanwhile, n-3 PUFAs are important in
balancingtheimmuneandinﬂammatoryfunctionsbyantagonizing
membrane n-6 AA and reducing PGE2 synthesis. PLA2 and COX2
are the two key enzymes for the PUFA metabolism and PGE2
synthesis. PLA2 is a large family of enzymes, with the iPLA2
(Ca2+-independent PLA2) preferentially functioning in n-3 DHA
metabolism and the cPLA2 (cytosolic PLA2) preferentially in n-
6 AA and n-3 EPA metabolism. COX2 is the key enzyme that
converts n-6 AA to PGE2, while 5-LO converts n-6 AA to LTB4.
PGE2 and LTB4 participate in immunoregulation, which might
be associated with somatic symptoms of depression and physical
manifestations of CVD. Proinﬂammatory cytokines, such as IL-
2a n dI F N - γ, activate PLA2 or COX2 and in turn increase levels
of n-6 AA. MDR PGP has eﬀects in depression by reducing the
access of glucocorticoids to the brain. n-3 PUFAs, on the other
hand, can inhibit MDR PGP. Enhancement is shown by a solid line,
attenuation by a dashed line. COX2 = cyclooxygenase 2; PLA2 =
phospholipase A2; 5-LO = 5-lipoxyge; MDR PGP = multidrug
resistance p-glycoprotein; CVD = cardiovascular disease.
proinﬂammatory PGE2 eﬀect, and in turn, normalize MDR
PGP overactivity and HPA hyperactivity.
2.2.3. Other Mechanisms. Stroke is largely associated with
depression and CVD in recent studies. One perspective is
that HPA axis hyperactivity contributes to risks for CVD
by the states of hypercholesterolemia, hypertriglyceridemia,
hypertension [11] and sympathoadrenal hyperactivity. As
microvascular changes contribute to risks for CVD by the
states of hypercholesterolemia, hypertriglyceridemia, hyper-
tension, and sympathoadrenal hyperactivity [11], stroke or
cerebrovascular lesions might also be involved in the patho-
genesis of depression, in particular, the late-life vascular
depression. On the other hand, patients with depression are
associated with a prothrombotic state of hypercortisolemia4 Cardiovascular Psychiatry and Neurology
and changes in platelet function related to HPA axis hyper-
activity, which may consequently increase risks for CVD
and stroke. n-3 PUFAs were shown to reduce mortality
of stroke in recent interventional studies, such as GISSI
[48]a n dD A R Ts t u d y[ 49]. n-3 PUFAs’ cardioprotection
eﬀects have also been supported by the ﬁndings showing
an inverse relation between n-3 PUFAs intake and stroke
[50]. Therefore, omega-3 PUFAs may also help to ﬁll out
the pieces among depression, stroke, and CVD. The role of
n-3 PUFAs in other mechanisms, including antiangiogenesis
and neurogensis of depression and CVD would need more
studies to examine.
3.Testing the Hypothesis
Since there are many studies showing that n-3 PUFAs are
promising interface connecting depression and CVD, more
clinical and basic studies are warrant for completing the
whole picture. Firstly, the role of COX2 polymorphisms in
depression and the role of PLA2 polymorphisms in CVD
need to be tested in case-control studies in clinical settings.
Although Pae et al. have shown higher frequency of G allele
of the PLA2 gene BanI polymorphism in 63 patients with
MDD compared with 117 healthy controls in a Korean
population [32]. As a direction for future studies, the result
needs replication in a larger sample. In addition, the eﬀect
of COX2 polymorphisms on MDD has never been tested.
In addition, the genetic eﬀects of COX2 and PLA2 as well
the therapeutic eﬀects of n-3 PUFAs on speciﬁc symptoms,
for example, depressive symptoms in CVD or somatic
symptoms, such as HRV, chest tightness, dyspnea, somatic
pain symptoms in depression, are also very important to
support our hypothesis. Secondly, speciﬁc enzyme activities
can inﬂuence the metabolism and synthesis of individual
PUFAs (e.g., iPLA2 preferentially on DHA metabolism and
cPLA2 preferentially on AA and EPA metabolism) [27, 28].
TheroleofiPLA2andcPLA2ondepressionandCVDshould
be clariﬁed in future studies. Finally, by animal studies, one
wouldbeabletoexplore whether(1)COX2enhancerswould
increase depression-like symptoms in mice and (2) PLA2
blockerswouldincreaseCVDrisksinmice.Iftheresultsfrom
basic study support the hypothesis of the role of COX2 in
depression and the role of PLA2 in CVD, we will be able to
take the step furtherinto genetic studies and explore whether
(1) mice of knockout cPLA2 genes would have increased
the risk of CVD, since more studies have focused on cPLA2
gene polymorphism and its association with depression; and
whether (2) mice of knockout COX2 genes would have
increased depression-like behaviors in animal models.
4. Implicationsof the Hypothesis
By 2020, pointed out the World Health Organization,
“depression will be second only to heart disease as a cause
of disability and premature death in established market
economies” [51]. n-3 PUFAs may link depression and
cardiovascular diseases based on numerous data about its
eﬀects on immunomodulation and normalization of HPA
axis functions. Hopefully, by accumulating more evidence
from future larger-scale studies, n-3 PUFAs might be used
as a remedy to cure one’s depression and mend one’s broken
heart.
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